Carcinoid Tumors: from the Past into the Future

Area of Science:

• Oncology
• Endocrinology
• Gastroenterology

Background:

• Carcinoid tumors are rare, slow-growing neoplasms with a propensity to affect all organs, most commonly the gastrointestinal tract and lungs.
• These tumors secrete various peptides and neuroamines, leading to diverse clinical presentations depending on the affected organ and secreted substances.
• Common symptoms include flushing, watery diarrhea, and bronchospasm, reflecting the neuroendocrine nature of these tumors.

Discussion:

• Diagnostic approaches include 24-hour urinary 5-hydroxyindoleacetic acid (5-HIAA) estimation for specificity and serum chromogranin for sensitivity, even in non-secretory cases.
• Advanced imaging modalities like Octreoscan and MIBG offer superior diagnostic value compared to standard CT or MRI alone for carcinoid tumors.
• Treatment necessitates a multidisciplinary strategy, encompassing surgical resection, debulking, embolization for liver metastases, somatostatin analogues, and chemotherapy.

Key Insights:

• The diagnosis of carcinoid tumors relies on a combination of biochemical markers and advanced imaging techniques.
• Multidisciplinary management is crucial for addressing the complexity of carcinoid tumor treatment.
• Novel molecular targeted therapies, including Sunitinib and Bevacizumab, demonstrate significant promise in improving treatment outcomes.

Outlook:

• Further research into molecular targeted therapies will likely enhance treatment efficacy and patient prognosis.
• Continued development of diagnostic tools may lead to earlier detection and more precise management of carcinoid tumors.
• A comprehensive, multidisciplinary approach remains the cornerstone for optimizing patient care and outcomes in carcinoid tumor management.